Wellbeing Digital Sciences Inc. KONEF
Set alert
At close · Oct 30
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.000001
- Prev close
- 0.00001
- Mkt cap
- 1.30K
- Vol
- 360
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.000001
- High
- 0.000001
News
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences enters deal to sell KGK Science stake to Cardinal Group
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) told investors it has struck a deal to sell its wholly-owned KGK Science subsidiary to Cardinal Group Inc for $2 million. The company said…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences subsidiary KGK Science starts patient recruitment for psilocybin and fragile X syndrome trial
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) reported that its subsidiary KGK Science on behalf of its client Nova Mentis has commenced patient recruitment for its first-of-its-kind, Health…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences says KGK subsidiary applies for Controlled Substance Dealers License; receives approval for research facility buildout
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned KGK Sciences Inc (KGK) subsidiary has applied for a Controlled Substance Dealers License from Health Canada,…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences caffeine replacement product boosted by preclinical study
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) told investors its subsidiary KGK Science Inc (KGK) has completed preclinical safety studies for its caffeine replacement coffee product, which…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences says KGK subsidiary receives exemption to begin psilocybin clinical trial
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) said its wholly-owned subsidiary KGK Sciences Inc. has received an exemption under Section 56 of the Controlled Drugs and Substances Act.
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences says KGK subsidiary gets OK to proceed with Phase II A clinical trial assessing psilocybin therapy for fragile X syndrome
Wellbeing Digital Sciences Inc (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has received a 'No Objection letter' from Health Canada, on behalf of client…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences subsidiary KGK Science awarded cannabis research license
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly owned subsidiary KGK Science Inc has been awarded an institution-wide cannabis research license for its state-of-the-art…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences says KGK Science subsidiary announces successful results of UP446 in immune response
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that a clinical study conducted by wholly-owned subsidiary KGK Science Inc has shown positive results of UP446 supplementation in…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences subsidiary KGK Science submits psilocybin and Fragile X Syndrome clinical trial application for client Nova Mentis
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its wholly-owned subsidiary KGK Science Inc has submitted a clinical trial application (CTA) on behalf of client Nova Mentis Life…
3 years ago proactiveinvestors.ca
Wellbeing Digital Sciences says Mindscape subsidiary treats its 1,000th patient
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its Mindscape Ketamine & Infusion Therapy, PLLC subsidiary has treated its 1,000th patient with IV Ketamine Therapy for…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences appoints Mohammad Sharifi to its board of directors
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said it has appointed Mohammad Sharifi to its board of directors, effective November 22, 2022. Sharifi will serve as a member of the Audit…
3 years ago proactiveinvestors.com
Wellbeing Digital Sciences says KGK Science subsidiary inks research services deal with Nova Mentis for Fragile X Syndrome clinical trials
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its wholly-owned KGK Science Inc subsidiary has entered into a research services agreement with Nova Mentis Life Science Corp…
3 years ago proactiveinvestors.ca
Wellbeing Digital Sciences says KGK Science subsidiary study successfully delivers CBD and THC through the skin
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc announced that its wholly-owned subsidiary KGK Science Inc has completed an open label study, in which Gefion Canada GT4 technology was used…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences and its subsidiary KGK Sciences hail Alberta government's move to regulate psychedelics use
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) and its wholly-owned subsidiary KGK Sciences Inc have announced that they applaud the efforts by the Alberta government to draw up a plan to…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences subsidiary KGK Sciences to submit psilocybin microdose capsule formulation to Health Canada
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its subsidiary KGK Sciences Inc has completed the chemistry, manufacturing, and controls (CMC) package to be used in support of a Phase…
4 years ago proactiveinvestors.ca
Wellbeing Digital Sciences to add three well-established pain management facilities to its clinical ecosystem
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc has announced that it has entered into a letter of intent to add three clinics into the company's clinical ecosystem, supporting its…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences says subsidiary KGK Sciences opens new clinical research centre in Ontario
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) announced that its wholly-owned subsidiary KGK Sciences Inc has opened its new clinical research center in London, Ontario, with the aim of…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences posts fiscal 4Q results; projects significant revenue from research and consulting contracts
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said that its revenue in the fourth quarter ended July 31, 2022, rose 2.5% year-over-year, adding that it expects significant revenue in the…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences says subsidiary KGK Sciences wins FDA's highest safety rating for ProGo ingredient on behalf of client Hofseth BioCare
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc says its wholly-owned subsidiary KGK Sciences Inc, on behalf of its client Hofseth BioCare ASA (HBC), has received a no-objection…
4 years ago proactiveinvestors.com
Wellbeing Digital Sciences says subsidiary IRP Health's new Toronto clinic has received approval from Veterans Affairs Canada for its Reactivation program
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc said its subsidiary IRP Health Ltd has received approval from Veterans Affairs Canada for its multidisciplinary Reactivation-branded therapy…